Low zinc status has been linked to a higher risk and faster progression of age-related macular degeneration (AMD), in part because zinc is concentrated in the retina and supports antioxidant defenses there. In the landmark AREDS trial, a supplement formula containing zinc (80 mg as zinc oxide), along with antioxidants, reduced the risk of progression to advanced AMD by about 25% in people with intermediate disease or advanced disease in one eye over roughly 5 years. Other research has shown that inadequate zinc intake is more common in older adults with AMD, reinforcing the idea that maintaining healthy zinc levels may be an important, and often overlooked, strategy for preserving macular health with age. This medication is commonly used for Hypertension.
Smailhodzic D, van Asten F, Blom AM, Mohlin FC, den Hollander AI, van de Ven JPH, et al. (2014) Zinc Supplementation Inhibits Complement Activation in Age-Related Macular Degeneration. PLoS ONE 9(11): e112682. Lengyel D, Török B. Erworbene vorübergehende Nachtblindheit bei Vitamin-A- und Zinkmangel bei Anorexia nervosa neun Jahre nach Nierentransplantation [Acquired temporary night blindness in vitamin A and zinc deficiency in anorexia nervosa nine years after kidney transplantation]. Klin Monbl Augenheilkd. 2006 May;223(5):453-5. German.Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Chojnacki C, Kaarniranta K. Zinc and Autophagy in Age-Related Macular Degeneration. Int J Mol Sci. 2020 Jul 15;21(14):4994. Benjamin P. Nicholson, et al. Chapter 37 - Zinc Deficiency and the Eye. Handbook of Nutrition, Diet and the Eye 2014, Pages 371-376.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies have shown that treatment with medications like Angiotensin Receptor Blockers (ARBs) can lead to zincuria, which is increased urinary excretion of zinc. This increased excretion may potentially lead to zinc deficiency in some individuals and therefore supplementation should be considered.